Annual review of anti-inflammatory medications

For the past 2 years I have jokingly labeled this month’s column my annual lifitegrast edition. Now that Xiidra has been on the market for a year, it is time to evaluate it in the context of its competitors. As this part of our world matures and becomes less controversial and more a part of care standards, Xiidra becomes another tool in the anti-inflammatory kit. After a year in the game, we are getting to know Shire while also learning some new things about the established players Allergan and Bausch (Read more...)

Full Story →